Here’s what you should know:
1. The combined solution is a blood-based test for recurrent tumors circulating in DNA.
2. The test can be conducted by a physician through a “simple blood test.”
3. Qiagen’s Head of Molecular Diagnostics Business Thierry Bernard said in a release the test is a non-invasive monitoring option for colorectal cancer patients.
4. The test is as effective as market standard tests for recurrent colorectal cancer.
5. The companies established a joint venture company, PreAnalytiX GmbH, to develop the test.
More articles on gastroenterology:
Majority of ulcerative colitis patients not achieving clinical, endoscopic remission — 5 key notes
GI leader to know: Dr. Sarah Brendler of the Cascade Endoscopy Center
GI center to know: Cascade Endoscopy Center
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
